Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kenei: Net Profits Decline Due to Contract Mfg Slump
November 22, 2004
- Sales Goal of Spiriva Set for \20 Bil.: NBI, Pfizer
November 22, 2004
- Shionogi to Make All-out Effort to Boost Sales of Crestor
November 22, 2004
- FPMAJ, JPMA Submit Petition on FY2005 Budget, Tax Reform
November 22, 2004
- Yamanouchi: Focusing on Rx Drugs Prior to Merger
November 22, 2004
- BUSINESS NEWS IN BRIEF
November 22, 2004
- Kyorin: Profits Down Due to Increase in R&D Spending in Full Year
November 22, 2004
- Sosei Aims at Sales of \21 Bil. in 2010
November 22, 2004
- Ono to Consider Independent Marketing Overseas Later: Mr Matsumoto
November 22, 2004
- Korosho Panel Tackles Problems of Off-Label Use of Drugs
November 22, 2004
- Kyorin: Overseas Sales Make Up for Domestic Slump
November 22, 2004
- REGULATORY NEWS IN BRIEF
November 22, 2004
- Taisho Postpones Some R&D Spending Due to Development Delays
November 22, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 22, 2004
- Toyama Chemical: License Fee of T-3811 Brings Sales Increase
November 22, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
November 22, 2004
- Ono: Mainstays Contribute to 2.2% Growth in Sales
November 22, 2004
- DIAGNOSTIC NEWS IN BRIEF
November 22, 2004
- Taisho: Harsh Weather Hurts Self-medication Div.
November 22, 2004
- Semiannual Business Results
November 22, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…